BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.
BioNexus Gene Lab Corp. (Nasdaq: BGLC) subsidiary MRNA Scientific Sdn. Bhd. has signed a strategic teaming agreement with Protech Builders Sdn. Bhd. to jointly develop and operate biogas plants in Malaysia. The three-year partnership aims to convert plantation and agricultural wastewater into renewable energy. Both companies will contribute up to RM1,000,000 (approx. USD 235,000) for project development activities.
Protech, with its G7 construction license and over 20 years of experience, brings technical expertise to the collaboration. The partnership leverages BGLC's market knowledge and Protech's engineering capabilities to capitalize on Malaysia's growing biogas market. This strategic alignment supports BGLC's mission for sustainability while enhancing revenue generation potential.
BioNexus Gene Lab Corp. (Nasdaq: BGLC) ha firmato un accordo di collaborazione strategica con la sua controllata MRNA Scientific Sdn. Bhd. e Protech Builders Sdn. Bhd. per sviluppare e gestire congiuntamente impianti di biogas in Malaysia. Questa partnership di tre anni ha l'obiettivo di convertire le acque di scarico agricole e di piantagione in energia rinnovabile. Entrambe le aziende contribuiranno fino a RM1.000.000 (circa 235.000 USD) per le attività di sviluppo del progetto.
Protech, con la sua licenza di costruzione G7 e oltre 20 anni di esperienza, porta competenze tecniche alla collaborazione. Questa alleanza strategica sfrutta le conoscenze di mercato di BGLC e le capacità ingegneristiche di Protech per capitalizzare il crescente mercato del biogas in Malaysia. Questo allineamento strategico supporta la missione di sostenibilità di BGLC, migliorando al contempo il potenziale di generazione di entrate.
BioNexus Gene Lab Corp. (Nasdaq: BGLC) ha firmado un acuerdo de colaboración estratégica con su subsidiaria MRNA Scientific Sdn. Bhd. y Protech Builders Sdn. Bhd. para desarrollar y operar conjuntamente plantas de biogás en Malasia. La asociación de tres años tiene como objetivo convertir las aguas residuales de plantaciones y agrícolas en energía renovable. Ambas empresas contribuirán con hasta RM1.000.000 (aproximadamente USD 235,000) para las actividades de desarrollo del proyecto.
Protech, con su licencia de construcción G7 y más de 20 años de experiencia, aporta experiencia técnica a la colaboración. Esta asociación aprovecha el conocimiento del mercado de BGLC y las capacidades de ingeniería de Protech para capitalizar el creciente mercado de biogás en Malasia. Este alineamiento estratégico apoya la misión de sostenibilidad de BGLC, mientras mejora el potencial de generación de ingresos.
BioNexus Gene Lab Corp. (Nasdaq: BGLC)의 자회사 MRNA Scientific Sdn. Bhd.는 Protech Builders Sdn. Bhd.와 전략적 협력 계약을 체결하여 말레이시아에서 바이오가스 플랜트를 공동으로 개발하고 운영하기로 하였습니다. 3년 협력의 목표는 농업 및 플랜테이션 폐수를 재생 에너지로 전환하는 것입니다. 두 회사는 프로젝트 개발 활동에 대해 최대 RM1,000,000(약 235,000 USD)까지 기여할 것입니다.
Protech은 G7 건설 면허와 20년 이상의 경험을 바탕으로 협력에 기술 전문성을 제공합니다. 이 파트너십은 BGLC의 시장 지식과 Protech의 엔지니어링 능력을 활용하여 말레이시아의 성장하는 바이오가스 시장을 기회로 삼습니다. 이러한 전략적 정렬은 BGLC의 지속 가능성 목표를 지원하며, 수익 창출 가능성을 향상시킵니다.
BioNexus Gene Lab Corp. (Nasdaq: BGLC) a signé un accord de collaboration stratégique avec sa filiale MRNA Scientific Sdn. Bhd. et Protech Builders Sdn. Bhd. pour développer et exploiter conjointement des usines de biogaz en Malaisie. Ce partenariat de trois ans vise à convertir les eaux usées des plantations et de l'agriculture en énergie renouvelable. Les deux entreprises contribueront jusqu'à RM1.000.000 (environ 235.000 USD) pour les activités de développement du projet.
Protech, avec sa licence de construction G7 et plus de 20 ans d'expérience, apporte une expertise technique à la collaboration. Ce partenariat exploite les connaissances de marché de BGLC et les capacités d'ingénierie de Protech pour tirer parti du marché croissant du biogaz en Malaisie. Cet alignement stratégique soutient la mission de durabilité de BGLC tout en améliorant le potentiel de génération de revenus.
Die BioNexus Gene Lab Corp. (Nasdaq: BGLC) hat mit ihrer Tochtergesellschaft MRNA Scientific Sdn. Bhd. und Protech Builders Sdn. Bhd. eine strategische Teamvereinbarung unterzeichnet, um gemeinsam Biogasanlagen in Malaysia zu entwickeln und zu betreiben. Die dreijährige Partnerschaft zielt darauf ab, Abwässer von Plantagen und der Landwirtschaft in erneuerbare Energie umzuwandeln. Beide Unternehmen werden bis zu RM1.000.000 (ca. 235.000 USD) für die Projektentwicklungsaktivitäten beitragen.
Protech bringt mit seiner G7-Baugenehmigung und über 20 Jahren Erfahrung technisches Know-how in die Zusammenarbeit ein. Diese Partnerschaft nutzt das Marktwissen von BGLC und die Ingenieursfähigkeiten von Protech, um vom wachsenden Biogas-Markt in Malaysia zu profitieren. Diese strategische Ausrichtung unterstützt die Mission von BGLC für Nachhaltigkeit und verbessert gleichzeitig das Potenzial zur Einnahmegenerierung.
- Strategic partnership to develop biogas plants in Malaysia
- Initial financial contribution of up to RM1,000,000 (USD 235,000) for project development
- Leveraging Protech's G7 construction license and 20+ years of experience
- Potential for multiple biogas projects over the next three years
- Expansion into the growing renewable energy sector in Malaysia
- None.
Insights
The entry of BioNexus Gene Lab Corp. into the biogas sector through its subsidiary MRNA Scientific marks a significant diversification move. This strategic partnership with Protech Builders leverages complementary strengths: BGLC's market knowledge and chemical expertise, combined with Protech's G7-licensed engineering capabilities.
The initial
Key points to consider:
- Diversification into a growing renewable energy market
- Leveraging of Protech's extensive experience (300+ projects) and highest-grade construction license
- Potential for both small and large-scale biogas installations
- Alignment with Malaysia's sustainability goals, potentially benefiting from government incentives
While this move shows promise, investors should note that it represents a significant shift from BGLC's core business, potentially introducing new operational risks and challenges. The success will largely depend on effective execution and the ability to secure and deliver profitable biogas projects.
KUALA LUMPUR, Malaysia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- MRNA Scientific Sdn. Bhd. ("MRNA"), a subsidiary of BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), and Protech Builders Sdn. Bhd. ("Protech"), a leading mechanical and electrical engineering construction firm in Malaysia, are pleased to announce the signing of a strategic teaming agreement (the “Agreement”) to jointly develop and operate biogas plants across Malaysia. This collaboration marks a significant step in both companies' efforts to contribute to Malaysia's growing renewable energy sector, particularly in the generation of biogas from plantation wastewater.
Strategic Collaboration for Sustainable Growth
Under this three-year Agreement, Protech and MRNA will pool their resources and expertise to identify, market, and execute biogas projects that convert plantation and agricultural wastewater into renewable energy. Protech and MRNA have agreed to together make an initial financial contribution of up to RM1,000,000 (Approx. USD 235,000) to fund feasibility studies and other project development activities.
The partnership will leverage the Company's extensive market knowledge and chemical raw material expertise, along with Protech’s proven capabilities in mechanical and electrical engineering. Protech holds a G7 construction license, the highest grade issued by the Construction Industry Development Board (CIDB) Malaysia, which allows them to undertake projects of any size and value without limitations. With over 20 years of experience and a portfolio of more than 300 successfully completed projects across Malaysia, including biogas facilities and power transmission systems, Protech is uniquely positioned to ensure the technical success and timely completion of these projects.
Projected Revenue and Growth Potential
The biogas market in Malaysia presents substantial growth opportunities. With the combined strengths of our Company and Protech, we anticipate securing multiple biogas projects over the next three years, ranging from small to large-scale installations.
A Step Toward a Sustainable Future
“This teaming agreement represents a strategic alignment of our strengths,” said Sam Tan, CEO of BioNexus Gene Lab Corp. “By combining the Company’s market insights and Protech’s engineering expertise, we are well-positioned to capitalize on the growing demand for biogas solutions in Malaysia. This partnership not only supports our mission to contribute to a sustainable future but also enhances our revenue generation capabilities.”
CW Wong, CEO of Protech Builders, added, “We are excited to partner with BGLC to develop biogas plants that will bring lasting environmental and economic benefits to Malaysia. Our extensive experience in constructing complex engineering systems, including biogas facilities and power transmission, combined with our G7 license, ensures that we can deliver top-quality projects that meet the highest industry standards.”
About BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp. is an emerging Biotech company and a leading supplier of chemical raw materials in Southeast Asia. Through its subsidiaries, BGLC operates in the Biotech and Chemical Supply Industries throughout Southeast Asia.
For more information, please visit www.bionexusgenelab.com.
About Protech Builders Sdn. Bhd.
Protech Builders Sdn. Bhd. is a renowned mechanical and electrical engineering firm in Malaysia, specializing in the installation, commissioning, and maintenance of complex engineering systems.
For more information, please visit www.protech.my.
Safe Harbor Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are not statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the biotech industry in Malaysia and the other markets the Company serves or plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in Malaysia and the other markets the Company serves or plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission (the “SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that arise after the date hereof.
Contact Information:
Investor Relations
BioNexus Gene Lab Corp
Email: ir@bionexusgenelab.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9eeb7b7c-f13c-444c-9380-17bb100d8b4d
FAQ
What is the purpose of the teaming agreement between BGLC and Protech Builders?
How much will BGLC and Protech Builders invest in the biogas project development?
What is the duration of the teaming agreement between BGLC and Protech Builders?